News in brief

June 2004
Reactions Weekly;6/19/2004, Issue 1006, p3
Presents news briefs on the pharmaceutical industry as of June 2004. Warnings issued by Biovail Pharmaceuticals on behavioral and emotional changes associated with the use of bupropion; Adverse reactions linked to parecoxib administration in Australia.


Related Articles

  • The predictivity of preliminary embryo-fetal development (EFD) studies: results of a retrospective survey in Japanese pharmaceutical companies. Okahashi, Noriko; Ikeda, Takashi; Kai, Shuichi; Komatsu, Shinichi; Matsui, Hajime; Yamashita, Yasuhiro; Yamamoto, Keiji; Sagami, Fumio // Journal of Toxicological Sciences;Feb2010, Vol. 35 Issue 1, p21 

    To explore the predictivity of dose range-finding (DRF) studies, we conducted a survey by sending out questionnaires to 72 Japanese pharmaceutical companies. The survey yielded data for 108 and 85 compounds for which any embryo-fetal development (EFD) toxicities were observed in the definitive...

  • Postmarketing identification of potential for harm a "key first step"  // Reactions Weekly;2/5/2005, Issue 1037, p3 

    Discusses research being done on an underrecognized challenge in evaluating postmarketing drug safety. Reference to a study by Doctor Dan M. Roden, published in the January 25, 2005 issue of "Circulation"; Factors in which the identification of potential adverse drug events depends.

  • Evolutionary Diagnosis of non-synonymous variants involved in differential drug response. Gerek, Nevin Z.; Li Liu; Gerold, Kristyn; Biparva, Pegah; Thomas, Eric D.; Kumar, Sudhir // BMC Genomics;2015, Vol. 16 Issue 1, p1 

    Background: Many pharmaceutical drugs are known to be ineffective or have negative side effects in a substantial proportion of patients. Genomic advances are revealing that some non-synonymous single nucleotide variants (nsSNVs) may cause differences in drug efficacy and side effects. Therefore,...

  • The Role of In Vitro ADME Assays in Antimalarial Drug Discovery and Development. Shearer, Todd W.; Smith, Kirsten S.; Diaz, Damaris; Asher, Constance; Ramirez, Julio // Combinatorial Chemistry & High Throughput Screening;Feb2005, Vol. 8 Issue 1, p89 

    The high level of attrition of drugs in clinical development has led pharmaceutical companies to increase the efficiency of their lead identification and development through techniques such as combinatorial chemistry and high-throughput (HTP) screening. Since the major reasons for clinical drug...

  • Pharma's year of trouble and strife. Frantz, Simon // Nature Reviews Drug Discovery;Jan2006, Vol. 5 Issue 1, p7 

    The article discusses the tragedy that happened in the pharmaceutical industry in 2005 relating to Vioxx incidents. The year began with the boost in the market of Vioxx (rofecoxib; Merck) and other cyclooxygenase-2 (COX2) inhibitors. However, side effects of the drugs were causing much damage to...

  • Patient's Safety Information Available On Anesthesia Drug Package Inserts. Takrouri, Mohamad Said Maani; Tayyem, Maher Mohammad // Internet Journal of Anesthesiology;2008, Vol. 16 Issue 2, p9 

    Background: Drug inserts are an important source of information for patients and physicians regarding the safety and proper administration of a drug. However, recent studies have found that inserts are still missing key information regarding a drug's safety and efficacy. The aim of this study...

  • Rifampicin interaction with ritonavir-boosted saquinavir.  // Reactions Weekly;2/19/2005, Issue 1039, p4 

    Reports on the move by Roche Pharmaceuticals Inc. to issue a health warning regarding the risk of combining the rifampicin and ritonavir/saquinavir drugs as part of a combination antiretroviral therapy. Potential for patients to develop hepatitis from using the combined drugs; Association...

  • Concordance of Severity Ratings Provided in Four Drug Interaction Compendia. Abarca, Jacob; Malone, Daniel C.; Armstrong, Edward P.; Grizzle, Amy J.; Hansten, Philip D.; Van Bergen, Robin C.; Lipton, Richard B. // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2004, Vol. 44 Issue 2, p136 

    Objective: To evaluate the agreement among drug-drug interaction (DDI) compendia as to designation of interactions as having the greatest clinical importance ("major" DDIs). Design: Cross-sectional, one-time evaluation. Setting: United States in fall 2001. Participants: Not applicable. ...

  • Approval times and the safety of new pharmaceuticals. Rudholm, Niklas // European Journal of Health Economics;Dec2004, Vol. 5 Issue 4, p345 

    This study examined the relationship between the approval times for new pharmaceuticals and the number of adverse drug reactions reported to the Swedish Medical Products Agency. Yearly time-series data concerning the number of adverse drug reactions, as well as data concerning prices and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics